{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:01:05Z","timestamp":1780995665850,"version":"3.54.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is a chronic, autoimmune joint disorder necessitating the use of complex, specialty medications. Health-system specialty pharmacies (HSSPs) operate under closed-loop models that have been shown to minimize barriers in medication access and adherence. However, there is a lack of literature to show if HSSP models improve RA disease activity scores. This study evaluates the impact HSSP services have on medication access, adherence, and RA disease activity compared to external (non-HSSP) specialty pharmacies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, observational cohort study included adult patients with RA who were prescribed a new specialty RA medication and had a clinical disease activity index (CDAI) score of &amp;gt;10. The primary outcome was the mean time to first fill of the RA specialty medication. Secondary outcomes were proportion of days covered (PDC) and mean CDAI change at 3 and 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 51 patients were evaluated, 24 in the HSSP group and 27 in the non-HSSP group. The HSSP group had a statistically significant shorter mean time to first fill (15 days vs 36.6 days, P = 0.02) and a higher mean PDC (0.92 vs 0.86, P = 0.04) when compared to the non-HSSP group. No significant differences were observed in mean CDAI change from baseline to 3 months (\u201310.0 vs \u20137.67, P = 0.51) and 6 months (\u20137.0 vs \u20137.61, P = 0.48).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study showed that an HSSP model reduced the mean time to first fill of RA specialty medication and increased medication adherence but did not significantly change CDAI scores. Future studies with a larger patient population and more consistent CDAI documentation should be conducted to evaluate clinical outcomes based on pharmacy models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf351","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:54:44Z","timestamp":1766580884000},"page":"661-668","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the impact of an integrated health-system specialty pharmacy model on clinical disease activity index scores in patients with rheumatoid arthritis"],"prefix":"10.1093","volume":"83","author":[{"given":"Thuyvan","family":"Phan","sequence":"first","affiliation":[{"name":"University of North Carolina Hospitals , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Datt","sequence":"additional","affiliation":[{"name":"UNC Health , Morrisville, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[{"name":"UNC Health , Morrisville, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tilkens","sequence":"additional","affiliation":[{"name":"Visante , St. Paul, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Liang","sequence":"additional","affiliation":[{"name":"UNC Health , Morrisville, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"6","key":"2026060904141123200_zxaf351-B1","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1185\/03007990902896386","article-title":"Trends in RA patients\u2019 adherence to subcutaneous anti-TNF therapies and costs","volume":"25","author":"Borah","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2026060904141123200_zxaf351-B2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.18553\/jmcp.2019.25.4.461","article-title":"Adherence, persistence, and expenditures for high-cost anti-inflammatory drugs in rheumatoid arthritis: an exploratory study","volume":"25","author":"Khilfeh","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"8, spec no.","key":"2026060904141123200_zxaf351-B3","first-page":"SP315","article-title":"Two-year adherence and costs for biologic therapy for rheumatoid arthritis","volume":"24","author":"Stolshek","year":"2018","journal-title":"Am J Manag Care"},{"issue":"10","key":"2026060904141123200_zxaf351-B4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/art.24114","article-title":"Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?","volume":"59","author":"Curkendall","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2026060904141123200_zxaf351-B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semarthrit.2017.12.010","article-title":"Do out-of-pocket costs affect medication adherence in adults with rheumatoid arthritis? A systematic review","volume":"48","author":"Heidari","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2026060904141123200_zxaf351-B6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","article-title":"Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the Corrona RA Registry","volume":"4","author":"Strand","year":"2017","journal-title":"Rheumatol Ther"},{"issue":"7","key":"2026060904141123200_zxaf351-B7","doi-asserted-by":"publisher","first-page":"882","DOI":"10.18553\/jmcp.2021.27.7.882","article-title":"Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy","volume":"27","author":"Peter","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"2026060904141123200_zxaf351-B8","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.37765\/ajmc.2020.88544","article-title":"Rheumatoid arthritis medication adherence in a health system specialty pharmacy","volume":"26","author":"Berger","year":"2020","journal-title":"Am J Manag Care"},{"issue":"(9)","key":"2026060904141123200_zxaf351-B9","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1093\/ajhp\/zxad341","article-title":"Evaluation of a health-system specialty pharmacy patient management program on achieving predefined clinical outcome measures","volume":"81","author":"O\u2019Reilly","year":"2024","journal-title":"Am J Health-Syst Pharm"},{"issue":"7","key":"2026060904141123200_zxaf351-B10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.18553\/jmcp.2023.29.7.732","article-title":"Primary medication nonadherence rates to specialty disease-modifying antirheumatic drugs for rheumatoid arthritis within a health system specialty pharmacy","volume":"29","author":"Petry","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"21","key":"2026060904141123200_zxaf351-B11","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/ajhp\/zxac212","article-title":"Health-system specialty pharmacy role and outcomes: a review of current literature","volume":"79","author":"Zuckerman","year":"2022","journal-title":"Am J Health-Syst Pharm"},{"issue":"suppl 1","key":"2026060904141123200_zxaf351-B12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/21556660.2019.1658305","article-title":"Impact of a specialty pharmacy benefit on rheumatoid arthritis medication adherence and functional status: a continuation study","volume":"8","author":"Kozlicki","year":"2019","journal-title":"J Drug Assess"},{"key":"2026060904141123200_zxaf351-B13","author":"Acheson"},{"issue":"suppl 11","key":"2026060904141123200_zxaf351-B14","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1002\/acr.20621","article-title":"Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA)","volume":"63","author":"Anderson","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"2026060904141123200_zxaf351-B15","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/acr.24042","article-title":"update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"2026060904141123200_zxaf351-B16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1&lt;22::AID-ANR4&gt;3.0.CO;2-9","article-title":"Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration","volume":"43","author":"Anderson","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2026060904141123200_zxaf351-B17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/art.22353","article-title":"Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis","volume":"55","author":"Finckh","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2026060904141123200_zxaf351-B18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/ajhp\/zxab392","article-title":"Proportion of days covered as a measure of medication adherence","volume":"79","author":"Loucks","year":"2022","journal-title":"Am J Health-Syst Pharm"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf351\/66134414\/zxaf351.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/12\/661\/66134414\/zxaf351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/12\/661\/66134414\/zxaf351.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:15:18Z","timestamp":1780992918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/12\/661\/8405496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,26]]},"published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf351","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,15]]},"published":{"date-parts":[[2025,12,26]]}}}